NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which is in Phase 2b clinical trail for Wet AMD and other retinal diseases; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. The company has a strategic licensing agreement with AffaMed and AskGene to develop and commercialize VIS-101 to Visara. It also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.